Announcements
- FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
- Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
- Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
- Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
- Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
- Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
- Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
- Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
- Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
- Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
More ▼
Key statistics
On Friday, Tiziana Life Sciences Ltd (0RP:FRA) closed at 0.625, -30.94% below its 52-week high of 0.905, set on Jun 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.625 |
---|---|
High | 0.625 |
Low | 0.625 |
Bid | 0.675 |
Offer | 0.725 |
Previous close | 0.70 |
Average volume | 25.00 |
---|---|
Shares outstanding | 103.09m |
Free float | 64.55m |
P/E (TTM) | -- |
Market cap | 76.28m USD |
EPS (TTM) | -0.1496 USD |
Data delayed at least 15 minutes, as of Jun 14 2024 07:07 BST.
More ▼